ARWR - Arrowhead Pharmaceuticals, Inc.
| Previous Close | 9.77 |
| Open | 9.81 |
| Bid | 9.70 x 900 |
| Ask | 10.25 x 1000 |
| Day's Range | 9.78 - 10.18 |
| 52 Week Range | 1.42 - 10.38 |
| Volume | 1,381,017 |
| Avg. Volume | 1,513,269 |
| Market Cap | 880.151M |
| Beta | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents•12 days ago
Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT
Q2 2018 Arrowhead Pharmaceuticals Inc Earnings Call
- Motley Fool•15 days ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can the momentum keep going for these sizzling-hot biotech stocks?
- MarketWatch•17 days ago
Four momentum stocks to watch amid earnings reports
In focus: Arrowhead Pharmaceuticals, Endocyte, Legacy Reserves and Impinj.
- Benzinga•17 days ago
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
- Associated Press•19 days ago
Arrowhead Research: Fiscal 2Q Earnings Snapshot
The Pasadena, California-based company said it had a loss of 18 cents per share. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ARWR earnings conference call or presentation 9-Feb-18 9:30pm GMT
Q1 2018 Arrowhead Pharmaceuticals Inc Earnings Call
- Associated Press•4 months ago
Arrowhead Research reports 1Q loss
The Pasadena, California-based company said it had a loss of 18 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Market Realist•4 months agoTaking Stock of Arrowhead Pharmaceuticals’ Financial Performance
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
Market Realist•4 months agoWhat Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
- Market Realist•4 months ago
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
- Market Realist•4 months ago
Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.
Market Realist•4 months agoAnalysts’ Recommendations for Arrowhead and Its Peers
Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.
- Motley Fool•4 months ago
Here's Why Arrowhead Pharmaceuticals Inc. Is Up Today
Find out why investors liked what this early-stage biotech had to say at this year's J.P. Morgan Healthcare Conference.
Capital Cube•5 months agoArrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017
Categories: Yahoo FinanceGet free summary analysis Arrowhead Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Arrowhead Pharmaceuticals, Inc. – Alnylam Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Shire PLC Sponsored ADR, Ligand Pharmaceuticals Incorporated, Inovio Pharmaceuticals, Inc. and Abeona Therapeutics, Inc. (ALNY-US, ... Read more (Read more...)
- Capital Cube•5 months ago
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 25, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Arrowhead Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ARWR-US. Comparing the performance and risk of Arrowhead Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Motley Fool•5 months ago
What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today
The company is seeking an important OK that could help it get back on track.
- InvestorPlace•5 months ago
3 Stocks to Watch on Wednesday: Arrowhead Pharmaceuticals Inc (ARWR), VeriFone Systems Inc (PAY) and Streamline Health Solutions Inc. (STRM)
Defensive telecoms gained 2.6% on a positive day for U.S. equities, while treasury bonds were unchanged. The S&P 500 Index gained 0.2%, the Dow Jones Industrial Average surged 0.5% and the Nasdaq Composite fell 0.2%.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT
Q4 2017 Arrowhead Pharmaceuticals Inc Earnings Call
- Zacks Small Cap Research•6 months ago
ARWR: New HBV Clinical Data of ARC-520 Presented at HEP DART Meeting
On December 6, Arrowhead (ARWR) presented new data of ARC-520 from its Phase II clinical study in patients with chronic hepatitis B virus (HBV) infection at the 22nd biennial HEP DART meeting held in Kona, Hawaii, from Dec. 3-7. The new data demonstrated that 2 of 3 (66.7%) HBeAg positive patients and 2 of 5 (40%) HBeAg negative patients treated with ARC-520 had a sustained host response that persisted after therapy was removed. In the 4 patients that had a sustained host response, the company observed reductions in HBsAg of 5.0, 3.1, 2.4, and 0.6 log10 from baseline, respectively.
- 24/7 Wall St.•6 months ago
Arrowhead Pharma Wins in Midstage Hepatitis Study
Arrowhead Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm presented new data from its midstage study for the treatment of hepatitis B infection.
